tetano
Editor, Senior Moderator
J Clin Med. 2020 May 7;9(5). pii: E1371. doi: 10.3390/jcm9051371.
Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort.
Di Micco P[SUP]1[/SUP], Russo V[SUP]2[/SUP], Carannante N[SUP]3[/SUP], Imparato M[SUP]1[/SUP], Rodolfi S[SUP]4[/SUP], Cardillo G[SUP]5[/SUP], Lodigiani C[SUP]4,[/SUP][SUP]6[/SUP].
Author information
Abstract
INTRODUCTION:
A novel highly pathogenic human coronavirus able to induce severe acute respiratory syndrome (SARS) has been recently recognized as the cause of the coronavirus disease 2019 (COVID-19) outbreak, which has spread rapidly from China to other countries. Little is known about laboratory prognostic markers in COVID-19 patients. The aim of our study was to describe the basic clotting parameters in COVID-19 patients and their prognostic role in different clinical forms of the disease.
MATERIAL AND METHODS:
We enrolled 67 COVID-19 patients admitted to the Emergency Department. A cohort of 67 age- and sex-matched non-COVID-19 patients with acute respiratory illness was used as a control group. For all patients, platelet count (PLT), prothrombin time (PT), activated thromboplastin time (aPTT), C-reactive protein (PCR), fibrinogen, and D-dimer were determined. The COVID-19 population was divided in two groups according to the presence or absence of SARS. The clotting factors values were compared between the groups.
RESULTS:
At admission, the COVID-19 patients showed statistically significant increased levels of fibrinogen (601.5 (480-747) vs. 455 (352.5-588.5) mg/dL; p = 0.0000064), and a higher percentage of patients had fibrinogen levels >400 mg/dL (86% vs.58%; p = 0.0054) compared to the control group. The levels of fibrinogen were higher in COVID-19 patients with SARS compared to those without SARS (747 (600.0-834.0) vs. 567 (472.5-644.50); p = 0.0003).
CONCLUSION:
Fibrinogen seems to increase early in COVID-19 patients and may be used as a risk stratification marker for the early detection of a subgroup of COVID-19 patient at increased risk to develop SARS, who might benefit from a different and thorough clinical surveillance and treatment.
KEYWORDS:
COVID-19; SARS-CoV2; alteration of hemostasis; disseminated intravascular coagulation; fibrinogen; prothrombin time
PMID:32392741DOI:10.3390/jcm9051371
Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort.
Di Micco P[SUP]1[/SUP], Russo V[SUP]2[/SUP], Carannante N[SUP]3[/SUP], Imparato M[SUP]1[/SUP], Rodolfi S[SUP]4[/SUP], Cardillo G[SUP]5[/SUP], Lodigiani C[SUP]4,[/SUP][SUP]6[/SUP].
Author information
Abstract
INTRODUCTION:
A novel highly pathogenic human coronavirus able to induce severe acute respiratory syndrome (SARS) has been recently recognized as the cause of the coronavirus disease 2019 (COVID-19) outbreak, which has spread rapidly from China to other countries. Little is known about laboratory prognostic markers in COVID-19 patients. The aim of our study was to describe the basic clotting parameters in COVID-19 patients and their prognostic role in different clinical forms of the disease.
MATERIAL AND METHODS:
We enrolled 67 COVID-19 patients admitted to the Emergency Department. A cohort of 67 age- and sex-matched non-COVID-19 patients with acute respiratory illness was used as a control group. For all patients, platelet count (PLT), prothrombin time (PT), activated thromboplastin time (aPTT), C-reactive protein (PCR), fibrinogen, and D-dimer were determined. The COVID-19 population was divided in two groups according to the presence or absence of SARS. The clotting factors values were compared between the groups.
RESULTS:
At admission, the COVID-19 patients showed statistically significant increased levels of fibrinogen (601.5 (480-747) vs. 455 (352.5-588.5) mg/dL; p = 0.0000064), and a higher percentage of patients had fibrinogen levels >400 mg/dL (86% vs.58%; p = 0.0054) compared to the control group. The levels of fibrinogen were higher in COVID-19 patients with SARS compared to those without SARS (747 (600.0-834.0) vs. 567 (472.5-644.50); p = 0.0003).
CONCLUSION:
Fibrinogen seems to increase early in COVID-19 patients and may be used as a risk stratification marker for the early detection of a subgroup of COVID-19 patient at increased risk to develop SARS, who might benefit from a different and thorough clinical surveillance and treatment.
KEYWORDS:
COVID-19; SARS-CoV2; alteration of hemostasis; disseminated intravascular coagulation; fibrinogen; prothrombin time
PMID:32392741DOI:10.3390/jcm9051371